chr17-41938634-C-CA
Position:
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PVS1PM2PP5_Moderate
The NM_031421.5(ODAD4):c.704dupA(p.His235fs) variant causes a frameshift change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Likely pathogenic (★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: not found (cov: 32)
Consequence
ODAD4
NM_031421.5 frameshift
NM_031421.5 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.11
Genes affected
ODAD4 (HGNC:25280): (outer dynein arm docking complex subunit 4) This gene encodes a tetratricopeptide repeat domain-containing protein that localizes to ciliary axonmenes and plays a role in the docking of the outer dynein arm to cilia. Mutations in this gene cause severely reduced ciliary motility and the disorder CILD35 (ciliary dyskinesia,primary, 35). Primary ciliary dyskinesia is often associated with recurrent respiratory infections, immotile spermatozoa, and situs inversus; an inversion in left-right body symmetry. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Apr 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 12 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 17-41938634-C-CA is Pathogenic according to our data. Variant chr17-41938634-C-CA is described in ClinVar as [Likely_pathogenic]. Clinvar id is 2671845.Status of the report is criteria_provided_single_submitter, 1 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ODAD4 | NM_031421.5 | c.704dupA | p.His235fs | frameshift_variant | 6/12 | ENST00000377540.6 | NP_113609.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ODAD4 | ENST00000377540.6 | c.704dupA | p.His235fs | frameshift_variant | 6/12 | 1 | NM_031421.5 | ENSP00000478589.1 | ||
ODAD4 | ENST00000591658.5 | n.704dupA | non_coding_transcript_exon_variant | 6/10 | 5 | ENSP00000477931.1 | ||||
ODAD4 | ENST00000593239.5 | n.*368dupA | non_coding_transcript_exon_variant | 6/6 | 3 | ENSP00000484975.1 | ||||
ODAD4 | ENST00000593239.5 | n.*368dupA | 3_prime_UTR_variant | 6/6 | 3 | ENSP00000484975.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD3 genomes
Cov.:
32
GnomAD4 exome Cov.: 32
GnomAD4 exome
Cov.:
32
GnomAD4 genome Cov.: 32
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Likely pathogenic
Submissions summary: Pathogenic:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
Primary ciliary dyskinesia Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute Of Molecular Biology And Genetics, Federal Almazov National Medical Research Centre | Dec 11, 2023 | The c.704dup variant leads to a frameshift (p.His235Glnfs*48) in ODAD4 (TTC25) gene, and is predicted to result in premature termination of translation. Bi-allelic loss-of-function variants in TTC25 are known as a genetic cause of primary ciliary dyskinesia (PMID:27486780). The patient was born to consanguineous parents and harbored the c.704dup in a homozygous state (the parents are heterozygous carriers). The c.704dup variant is absent in publicly available population and clinical databases (gnomAD, dbSNP, ClinVar). For these reasons, this variant has been classified as Likely Pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
No publications associated with this variant yet.